At present, there exists a clear consensus on numerous molecular abnormalities associated with AML prognosis such as NPM1 and FLT3 mutations [4,5]; thus, identifying novel prognostic genes has become pivotal in determining risk factors for AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.